Lundbeck increased revenue by 5% driven by US sales growth of 33% leading to improved profitability and increased financial guidance for 2016
HIGHLIGHTS
- Revenue reached DKK 7,521 million in the first half of 2016 representing an increase of 5% in both reported and local currencies compared to the same period last year
- Total revenue has delivered a better performance than expected driven by Xenazine® and key products
- US revenue increased 33% (31% in local currency) to DKK 3,840 million
- Revenue in International Markets declined 5% (unchanged in local currencies) to DKK 2,033 million
- Europe declined 26% (25% in local currencies) to DKK 1,453 million
- Revenue from key products grew 99% (99% in local currencies) to DKK 2,902 million in the period representing 39% of total revenue
- Abilify Maintena® sees strong growth reaching DKK 534 million. The growth of 93% (94% in local currencies) was driven by all regions, but particularly by Europe
- Brintellix®/Trintellix sales grew 103% and reached DKK 482 million, with non-US markets contributing DKK 220 million or 46% of total Brintellix sales
- Northera® sales reached DKK 449 million, up 203% (201% in local currency)
- Onfi® continues its solid performance growing 42% (40% in local currency) to DKK 1,128 million
- Rexulti® was launched in the US in August 2015 and revenue reached DKK 309 million
- In the first half of 2016, the EBIT-margin reached 12.7% compared to a negative margin of 67.6% in the same period in 2015. In 2015, EBIT included an impairment loss of DKK 4.8 billion
- Following the solid performance, Lundbeck now expects revenue of around DKK 14.6-15.0 billion and EBIT is expected to reach DKK 1.5-1.7 billion for 2016 compared to previously DKK 14.2-14.6 billion and DKK 1.3-1.5 billion, respectively
In connection with the financial report, Lundbeck’s President and CEO, Kåre Schultz said:
“I am very pleased with the continued strong sales growth of our key products and the increase of our financial guidance. We are on track to improve our profitability and I am excited about our R&D pipeline.”
DKK million | H1 2016 | H1 2015 | Growth |
Reported Revenue | 7,521 | 7,192 | 5% |
Reported EBIT | 952 | (4,865) | - |
Reported EPS | 2.12 | (20.26) | - |
Reported EBIT margin | 12.7% | (67.6%) | - |
Core Revenue* | 7,521 | 7,192 | 5% |
Core EBIT* | 1,475 | 351 | 320% |
Core EBIT margin* | 19.6% | 4.9% | 300% |
*For definition of the measures “Core Revenue” and “Core EBIT”, see note 3 Core reporting